Abstract
Fractionation of plasma is a way to prepare a number of proteins for clinical use, of great value in treatment and prevention of a number of diseases and disease states. Of special importance are the coagulation factor concentrates used for treatment of hemophilia. In treatment of hemophilia A Factor VIII concentrates are used and for treatment of hemophilia B Factor IX concentrates. Before those concentrates were developed there was essentially no treatment for hemophilia patients and life-expectancy was poor. Average lifespan was around 16 years. With the introduction of the Factor VIII and IX concentrates in the 60ties life has completely changed for hemophilia patients. They now can live an almost normal life.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Choo KH, Gould KJ, Rees DJG, Brownlee GG. Molecular cloning of the gene for human antihaemophiliac Factor IX. Nature 1982;299:178–80.
Kurachi K, Davie EW. Isolation and characterization of a CDNA coding for human Factor IX. Proc Natl Acad Sci (USA) 1982;79:6461–4.
De la Salle H, Altenburger W, Elkaim R et al. Active7 -carboxylated human Factor IX expressed using recombinant DNA techniques. Nature 1985;316: 268–70.
Busby S, Kumar A, Joseph M et al. Expression of active human Factor IX in transfected cells. Nature 1985;316:271–3.
Rotblat F, O’Brien D.P, O’Brien FJ, Goodall AH, Tuddenham EGD. Purification of human Factor VIII:C and characterization by western blotting using monoclonal antibodies. Biochemistry 1985;24:4294–300.
Andersson L-O, Forsman N, Huang K et al. Isolation and characterization of human Factor VIII: Molecular forms in commercial Factor VIII concentrate, cryoprecipitate and plasma. Proc Natl Acad Sci (USA) 1986;83:2979–83.
Gitschier J, Wood WI, Goralka TM et al. Characterization of the human Factor VIII gene. Nature 1984;312:326–30.
Toole JJ, Knopf JL, Wozney JM et al. Molecular cloning of a CDNA encoding human antihemophilic factor. Nature 1984;312:342–7.
High KA, White II GC, McMillan CW, Macik BG, Roberts HR. In vivo characteristics of rDNA F VIII: The impact for the future in hemophilia care. In: Smit Sibinga CTh, Das C, Overby LR (eds). Biotechnology in blood transfusion. Martinus Nijhoff Publ: Boston/Dordrecht/Lancaster 1988:223–230.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Andersson, LO. (1988). Production of Clotting Factors Through Biotechnology. In: Sibinga, C.T.S., Das, P.C., Overby, L.R. (eds) Biotechnology in blood transfusion. Developments in Hematology and Immunology, vol 21. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1761-6_12
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1761-6_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8988-3
Online ISBN: 978-1-4613-1761-6
eBook Packages: Springer Book Archive